Evidence Table N1. Articles/arms for class OTHER.

CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

N.01.01 266 Sunder vati 500 mg oral tid. Mild soap and water. Placebo 500 mg oral tid. Mild soap and water. Continuous (M)

Gugulipid is standardized 

extract of Commiphora 

Mutrel, an Indian 

medicinal plant. 

N.01.02 325 Continuous

Discrete

Gugulipid 25 mg oral bid. Tetracycline 500 mg oral bid. 

Frequency and dose 

unknown; deep sea shark 

liver oil. 

N.01.03 94 Continuous

Discrete

0.15 % topical (can't 

say)

Isolutrol 5 % topical (can't 

say)

Benzoyl 

peroxide

Leaves crushed in palm 

and juice applied at night 

as thin smear over lesions. 

Mild soap in morning.

Dose maintained or 

reduced at 4 weeks 

depending on response. 

Sulfur lotion twice a 

day after washing with 

mild soap.

N.01.04 17 Ocimum No dose information. Discrete

basilicum

Tetracycline 500 mg oral bid. 

N.01.05 18 Melaleuca alternifolia. Continuous

Discrete

5 % topical (can't 

say)

Tea tree oil Benzoyl 5 % topical ()

peroxide

N.02.01 175 To one side of the face. Continuous

Discrete

Clobetasol No dose information. 

propionate

Vehicle No dose information. 

N.02.03 288 Hydrocortisone 1 topical bid. Hydrocortisone 1 % topical bid. Discrete (M)

Sulphur 4 % topical bid. 

N.02.04 228 Methylpredniso 2.5 % topical bid. Discrete

lone

Neomycin 2.5 % topical bid. 

Vehicle No dose information. 

N.02.05 102 5 % topical (can't Discrete

say)

Sulphur

0.25 % topical (can't 

say)

Neomycin

0.25 % topical (can't 

say)

Methylpredniso

lone

Vehicle No dose information. 

Vehicle for NeoMedrol®. Physically 

346 Aluminum 10 % topical qd. Discrete

chlorhydroxide

Placebo No dose information. 

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 1 of 6
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

distinguishable from 

active drug. 

Sulfur 5 % topical qd. 

Methylpredniso 0.25 % topical qd. 

lone

Neomycin 0.25 % topical qd. 

N.02.06 228 Methylpredniso 2.5 % topical bid. Modified placebo. Discrete

lone

Neomycin 2.5 % topical bid. 

Sulphur 50 % topical bid. 

Aluminum 100 % topical bid. 

chlorhydroxide

Physically 

indistinguishable from 

Neo-Medrol®. 

347 Aluminum 10 % topical qd. Discrete

chlorhydroxide

sulfur 0.25 % topical qd. 

Methylpredniso 0.25 % topical qd. 

lone

Neomycin 0.25 % topical qd. 

Sulfur 5 % topical qd. 

Usual therapeutic 

measures.

Colored to look like 

gamma globulin. 

N.03.01 189 2 cc other (q 2 Discrete

weeks)

Gammaglobulin

2 cc other (q 2 

weeks)

Placebo

preparation of Tfd: human 

leucocyte dialysate was 

prepared from a pool of 

citrated buffy coats 

obtained from the Finnish 

Red Cross Blood 

Transfusion Service and 

fractionated on Sephadex® 

G-10 as previously 

described (Ashorn, R. Acta. 

Pathol. Microbiol Scand 

ICI 1982; 90: 331-7). 

Soap/low pH cleanser 

(average), and, if 

necessary, a cream 

containing salicylic acid 

and sulfur.

preparation of Tfd: 

human leucocyte 

dialysate was prepared 

from a pool of citrated 

buffy coats obtained 

from the Finnish Red 

Cross Blood 

Transfusion Service 

and fractionated on 

Sephadex® G-10 as 

previously described 

(Ashorn, R. Acta. 

Pathol. Microbiol 

Scand ICI 1982; 90: 

331-7). Soap/low pH 

cleanser (average), 

and, if necessary, a 

cream containing 

salicylic acid and 

sulfur.

N.03.02 15 Unfractionated No dose information. Discrete

human 

dialyzable 

transfer factor

Fractionated No dose information. 

human 

dialyzable 

transfer factor

N.03.03 222 Staphylococcal 0.5 ml other (q 4 .1 ml, .2 ml, .4 ml, .8 ml & Vehicle 0.5 cc other (q 4 Soft soap, dietary Discrete

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 2 of 6
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

1.0 ml q 4 days. Soft soap, 

dietary discretion, clean 

nails.

toxoid days) days) discretion, clean nails.

N.04.01 297 Hydrocortisone 4 % topical bid. Discrete

Chloramphenic 4 % topical bid. 

ol

Vehicle No dose information. 

N.04.02 224 Normal skin toilet. Continuous

Discrete

Buttoxethyl No dose information. 

nicotinate

Hydrocortisone No dose information. 

Chloramphenic No dose information. 

ol

Sulphur No dose information. 

Vehicle No dose information. 

N.04.03 142 Normal skin toilet. Normal skin toilet. Continuous

Discrete

Hydrocortisone 4 % topical qhs. 

Sulphur 32 % topical qhs. 

Chloramphenic 4 % topical qhs. 

ol

Sulphur 32 % topical qhs. 

Chloramphenic 4 % topical qhs. 

ol

N.04.04 115 Bid for first 4 days. Bid for first 4 days. Continuous

Discrete

Sulphur 32 % topical qhs. 

Hydrocortisone 4 % topical qhs. 

Chloramphenic 4 % topical qhs. 

ol

Sulphur 32 % topical qhs. 

Hydrocortisone 4 % topical qhs. 

Frequency qd for 1 

week then bid. 

N.04.05 75 Continuous

Discrete

Sulphur No dose information. 

Hydrocortisone No dose information. 

Chloramphenic No dose information. 

ol

Benzoyl 5 % topical bid. 

peroxide

100 rad 3 times a week 

until dose achieve. 

Same set-up as Grenz 

arm, but with lead plate 

blocking radiation. 

N.05.01 138 Grenz rays 1600 rad other (tiw) Placebo No dose information. Discrete

1600 rads initially, 4-8 

week pause, then 800 rads. 

Same set-up as Grenz 

arm, but with lead plate 

blocking radiation. 

139 Grenz rays 2400 rad topical (tiw) Placebo No dose information. Discrete

10 kv irradiation frequency 

100 rad qd x 6 then 100 

rad or 300 rad 9 week x 4. 

179 Grenz rays 1200 rad other qd. Placebo No dose information. Discrete

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 3 of 6
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

50k irritation frequency 

100 rad qd x 6 then 100 

rad qwh x 6 or 300 rad 9 

weeks x 4. 

N.05.01 180 Grenz rays 1200 rad other qd. Placebo No dose information. Discrete

350 200 rads other (M)

(monthly)

Grenz rays Hexachlorophe No dose information. 

ne

Placebo No dose information. 

Only right side treated. 

Some on oral antibiotics or 

Vitamin A.

Only right side treated. 

Some on oral 

antibiotics or Vitamin 

A.

N.05.02 215 Comedone No dose information. Discrete

extraction

Comedone No dose information. 

extraction

Only right side treated. 

Some on oral antibiotics or 

Vitamin A.

216 Comedone No dose information. Discrete

extraction

Untreated No dose information. 

EMLA topical anaesthetic 

90 min prior to treatment. 

4 patients tab oral antibacterials..

Treatment frequency 

varied between qd and 

bid, depending on 

patient's tolerance. 4 

patients oral antibacterial..

N.05.03 31 Continuous

Discrete

Tretinoin 0.025 % topical bid. 

N.05.04 32 No topical anaesthetic.. Topical anesthesia.. Continuous

Signed a commitment to 

medications use and a 

chance to win $1 for every 

self monitoring card 

returned. 

Asked to keep a record 

of use of the benzoyl 

peroxide. 

N.06.02 109 Benzoyl No dose information. Continuous (M)

peroxide

Benzoyl No dose information. 

peroxide

The first two sessions were 

biofeedback-assisted 

relaxation training. The 

third and fourth were 

biofeedback-assisted cuecontrolled relaxation 

training. Session 5 though 

12 were biofeedback 

assisted cue-controlled 

relaxation and guided 

No treatment other 

than standard care at 

the clinic was 

administered in this 

group. This arm was 

"constructed" 

retrospectively and 

were not directly 

involved in the study.. 

Topical benzoyl 

N.06.03 172 Erythromycin No dose information. Continuous

Benzoyl No dose information. 

peroxide

Relaxation- No dose information. 

imagery

Erythromycin No dose information. 

Benzoyl No dose information. 

peroxide

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 4 of 6
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

cognitive imagery 

training.. Topical benzoyl 

peroxide and sulfur lotion, 

topical erythromycin 

ointment, and attendance 

at the clinic for lesion 

extraction..

peroxide and sulfur 

lotion, topical 

erythromycin ointment, 

and attendance at the 

clinic for lesion 

extraction..

Continued baseline 

ancillary treatment.

Continued baseline 

ancillary treatment.

N.06.04 178 Hydrochlorthia 50 mg oral bid. Discrete

zide

Vehicle No dose information. 

Soap washing tid; 

astringent; nightly use of a 

sulfur ointment.

284 Hydrochlorthia 25 mg oral tid. Discrete

zide

Placebo No dose information. 

Placebo of Tetracycline. Tetragel® placebo + 

ibuprofen placebo. 

N.06.045 349 Continuous

Discrete

Placebo No dose information. (M)

Ibuprofen 600 mg oral qid. 

Placebo No dose information. 

(ibuprofen)

Placebo No dose information. 

No change of topical 

therapy was made.

No change of topical 

therapy was made.

N.06.05 110 Tolbutamide No dose information. Vehicle No dose information. Discrete

N.07.01 64 Zinc sulfate 2 % topical tid. Vehicle No dose information. Continuous

N.07.02 3 After meals. After meals. Continuous

Discrete

Zinc sulfate 220 mg oral bid. Placebo No dose information. 

2 capsules 20 minutes 

before breakfast. 

2 capsules 20 minutes 

before breakfast. 

91 Continuous

Discrete

Zinc gluconate 200 mg oral qd. Placebo No dose information. 

Identical in behavior to 

zinc. 

133 Continuous

Discrete

Zinc sulphur 45 mg oral tid. Placebo No dose information. 

Dosage corresponds to 45 

mg zn 2+. Local treatment 

with salicylic acid &/or 

liniment of sulfur 

corresponds to 45 mg zn 

2+.

163 Continuous

Discrete

Zinc sulfate 0.2 g oral bid. Placebo No dose information. 

211 Zinc sulfate 600 mg oral qd. Placebo Continuous

4 week washout period with 

placebo. Bland soap, diet 

low in zinc.

4 week washout period 

with placebo. Bland 

soap, diet low in zinc.

259 Zinc sulfate 137 mg oral tid. Continuous

monohydrate

Vehicle No dose information. 

336 Zinc sulfate 300 mg oral bid. Dose of 300mg report Vehicle 300 mg oral bid. Continuous

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 5 of 6
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

represents weight of 

unknown amount of zinc 

plus lactose. 

Discrete

Usual soaps, OTC meds 

except benzoyl peroxide.

341 Continuous

Discrete

Zinc sulfate 220 mg oral tid. Placebo No dose information. 

Tablet dissolved in water 

three times a day after 

meals. 

Tablet dissolved in 

water three times a day 

after meals; identical 

appearance and taste 

to treatment. 

342 Continuous

Discrete

Zinc sulfate 0.2 g oral tid. Vehicle No dose information. 

No dose given: "1 three 

times daily". 

N.07.03 74 Zinc No dose information. Continuous

sulfate/citrate 

complex

Tetracycline 250 mg oral bid. 

Tid 2 wks; bid 2 wks; 

qd 8wks. 

232 Zinc sulfate 0.2 gm oral tid. Oxytetracycline 250 mg oral qd. Continuous

N.08.01 108 Placebo (oral) No dose information. Continuous (M)

Zinc acetate 1.2 % topical bid. 

Erythromycin 4 % topical bid. 

Placebo (oral) No dose information. 

Placebo No dose information. 

(topical)

Switched to erythro + 

zinc after 12 weeks. 

301 Continuous

Discrete

Zinc 1.2 % topical bid. 

Erythromycin 4 % topical bid. 

Vehicle No dose information. 

Single product. Vehicle diisopropyl 

sebacate 27%. 

321 Zinc acetate 1.2 % topical bid. Vehicle No dose information. Continuous

N.08.02 28 Zinc acetate No dose information. Plain soap/cleansing. Plain soap/cleansing. Continuous

Erythromycin No dose information. 

Erythromycin 4 % topical bid. 

147 Continuous

Discrete

Zinc No dose information. 

Erythromycin 4 % topical bid. 

Erythromycin 2 % topical bid. 

N.08.03 300 Continuous

Discrete

Zinc 1.2 % topical bid. 

Erythromycin 4 % topical bid. 

Clindamycin 1 % topical bid. 

phosphate

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table =N HEADING: Page 6 of 6